Genexine Changes Phase 2 and 3 Clinical Trial Plans for COVID-19 Vaccine
[Asia Economy Reporter Junho Hwang] Genexine announced on the 30th that it has applied for a change in the Phase 2/3 clinical trial plan for its COVID-19 preventive DNA vaccine (GX-19N).
Genexine changed the target population from healthy adults to adults who have previously been vaccinated, shifting the strategy to a clinical trial aimed at verifying the protective efficacy as a booster shot (additional vaccination).
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
The company explained, "Through conducting global Phase 2/3 clinical trials, we expect to demonstrate the protective efficacy of GX-19N compared to placebo via T-cell immunity and verify the vaccine's effectiveness against breakthrough infections."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
